Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $19.00 Consensus PT from Analysts

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $19.00.

Several analysts recently weighed in on ARTV shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Thursday, October 30th. Jefferies Financial Group upgraded shares of Artiva Biotherapeutics to a “strong-buy” rating in a research report on Tuesday, November 18th. HC Wainwright lifted their price target on shares of Artiva Biotherapeutics from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. Wedbush increased their price objective on Artiva Biotherapeutics from $18.00 to $23.00 and gave the company an “outperform” rating in a research report on Friday, October 17th. Finally, Needham & Company LLC restated a “buy” rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a report on Friday, October 17th.

Insider Buying and Selling

In other Artiva Biotherapeutics news, CEO Fred Aslan sold 25,500 shares of the firm’s stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $6.00, for a total value of $153,000.00. Following the completion of the transaction, the chief executive officer directly owned 356,721 shares in the company, valued at $2,140,326. This trade represents a 6.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders have sold 35,062 shares of company stock worth $193,670 over the last ninety days. 21.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several hedge funds have recently made changes to their positions in the company. Ground Swell Capital LLC purchased a new position in Artiva Biotherapeutics during the 2nd quarter worth approximately $38,000. Prelude Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the third quarter worth $41,000. Bank of America Corp DE grew its holdings in shares of Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after buying an additional 11,190 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Artiva Biotherapeutics during the second quarter valued at $48,000. Finally, Bridgeway Capital Management LLC purchased a new stake in Artiva Biotherapeutics in the 2nd quarter worth about $53,000.

Artiva Biotherapeutics Stock Down 5.7%

Shares of Artiva Biotherapeutics stock opened at $4.60 on Friday. The firm has a market cap of $112.93 million, a P/E ratio of -1.78 and a beta of 2.92. Artiva Biotherapeutics has a fifty-two week low of $1.47 and a fifty-two week high of $7.94. The business has a 50-day moving average price of $3.92 and a 200 day moving average price of $3.29.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.04. As a group, equities research analysts anticipate that Artiva Biotherapeutics will post -4.95 earnings per share for the current year.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.